ADMA Biologics Inc. (ADMA)
| Market Cap | 218.41M |
| Revenue (ttm) | 40.30M |
| Net Income (ttm) | -66.90M |
| Shares Out | 87.70M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $2.31 |
| Previous Close | $2.35 |
| Change ($) | -0.04 |
| Change (%) | -1.70% |
| Day's Open | 2.37 |
| Day's Range | 2.26 - 2.41 |
| Day's Volume | 2,299,387 |
| 52-Week Range | 1.45 - 4.20 |
Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Achieved Fourth Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue Quarter for the Company Since Inception
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketi...
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketi...
ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
ADMA Biologics recently reported its Q3 earnings with a beat on EPS and revenue. In addition, the company reported encouraging commercial progress for its IVIG products despite the COVID-19 he...
RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated...
ADMA Biologics' (ADMA) CEO Adam Grossman on Q3 2020 Results - Earnings Call Transcript
Adma Biologics (ADMA) delivered earnings and revenue surprises of 9.52% and 7.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Generated Total Revenues of $ 28. 3 Million for the First Nine Months of 2020 , Reflecting a 63 % Increase Over the Same Prior Year Period
Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.
Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated...
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedica...
ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify High Titer Convalescent Plasma for Use in Both Treating COVID-19 Patients and for Creating COVID-19 Hyperimmune Globulins
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedica...
The pandemic highlights how far medical science has come. It also highlights how exciting the future is.
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
Shares of ADMA Biologics are on the move following the FDA's authorization of convalescent plasma for the treatment of COVID-19 patients.
Convalescent plasma holds promise for treating COVID-19, but it's still unproven.
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts be...
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...
The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.
ADMA Biologics has shown substantial progress of late, opening another plasma collection facility and growing sales 78% in H1 2020 over the prior year.
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2020 Results - Earnings Call Transcript
Adma Biologics (ADMA) delivered earnings and revenue surprises of -21.05% and -24.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Generated Total Revenues of $18.0 Million for the First Half of 2020, Reflecting a 78% Increase Over First Half of 2019
Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
RAMSEY, N.J. and BOCA RATON, Fla. and KNOXVILLE, Tenn., July 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company ded...
RAMSEY, N.J. and BOCA RATON, Fla., June 23, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturi...
Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.
RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturin...
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q1 2020 Results - Earnings Call Transcript
Adma Biologics (ADMA) delivered earnings and revenue surprises of -100.00% and -4.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics: A Compelling Value At Current Price Levels
ADMA Biologics: Not Immune To Coronavirus Sell-Off Despite Their Ability To Help
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q4 2019 Results - Earnings Call Transcript
Company Offers Assistance with Coronavirus Global Health Initiatives
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturi...
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marke...
The company's secondary stock offering was priced below its prior-day closing price.
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicate...
About ADMA
ADMA Biologics, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposur... [Read more...]
| Industry Biotechnology | Founded 2004 |
| CEO Adam S. Grossman | Employees 313 |
| Stock Exchange NASDAQ | Ticker Symbol ADMA |
Financial Performance
In 2019, ADMA Biologics's revenue was $29.35 million, an increase of 72.79% compared to the previous year's $16.99 million. Losses were -$48.28 million, -26.56% less than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for ADMA Biologics stock is "Buy." The 12-month stock price forecast is 8.83, which is an increase of 282.25% from the latest price.